Envista (NYSE:NVST - Get Free Report) had its price target raised by investment analysts at Piper Sandler from $17.00 to $19.00 in a report released on Friday,Benzinga reports. The firm currently has a "neutral" rating on the stock. Piper Sandler's price objective would suggest a potential downside of 8.57% from the stock's current price.
NVST has been the subject of several other reports. Bank of America reduced their price target on Envista from $26.00 to $23.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Evercore ISI raised their price objective on shares of Envista from $19.00 to $23.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Robert W. Baird raised shares of Envista from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $21.00 to $23.00 in a research report on Tuesday, May 27th. Baird R W upgraded shares of Envista from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 27th. Finally, UBS Group raised their price target on shares of Envista from $18.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday. One analyst has rated the stock with a sell rating, nine have issued a hold rating, four have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $20.92.
Read Our Latest Research Report on Envista
Envista Stock Up 10.0%
Envista stock traded up $1.89 during trading hours on Friday, hitting $20.78. The company had a trading volume of 6,198,369 shares, compared to its average volume of 2,233,196. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.12 and a quick ratio of 1.82. The firm has a market capitalization of $3.52 billion, a P/E ratio of 64.94, a price-to-earnings-growth ratio of 1.32 and a beta of 1.00. The firm's fifty day moving average is $19.41 and its 200-day moving average is $18.61.
Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. Envista had a net margin of 2.11% and a return on equity of 4.89%. The business had revenue of $682.10 million for the quarter, compared to analysts' expectations of $638.21 million. During the same period in the previous year, the company posted $0.11 EPS. Envista's revenue was up 7.7% on a year-over-year basis. On average, research analysts forecast that Envista will post 1 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of NVST. Alliancebernstein L.P. raised its holdings in Envista by 1,985.1% in the 1st quarter. Alliancebernstein L.P. now owns 4,550,789 shares of the company's stock valued at $78,547,000 after acquiring an additional 4,332,541 shares in the last quarter. Brickwood Asset Management LLP bought a new stake in shares of Envista during the fourth quarter valued at approximately $40,037,000. Norges Bank acquired a new position in shares of Envista in the fourth quarter valued at $38,052,000. Dimensional Fund Advisors LP raised its stake in shares of Envista by 24.0% in the first quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company's stock valued at $144,760,000 after purchasing an additional 1,625,206 shares in the last quarter. Finally, Pzena Investment Management LLC lifted its position in Envista by 160.7% in the first quarter. Pzena Investment Management LLC now owns 2,294,257 shares of the company's stock worth $39,599,000 after purchasing an additional 1,414,080 shares during the period.
Envista Company Profile
(
Get Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories

Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.